Completed PHASE1 INTERVENTIONAL NCT01319903

Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29

A Single Ascending, Placebo-controlled, Double-blind Study in Healthy Male Subjects to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the New Humanized Monoclonal Antibody CaCP29

Sponsor: InflaRx GmbH

Conditions Drug Safety

Interventions CaCP29, a humanized monoclonal antibody

Updated 5 times since 2017 Last updated: Jan 12, 2012 Started: Mar 31, 2011 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01319903, this PHASE1 trial focuses on Drug Safety and remains completed. Sponsored by InflaRx GmbH, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

InflaRx GmbH

Data source: InflaRx GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Neuss, Germany